
Onselex Pharmaceuticals is an oncology company advancing the next generation of nanomedicine to change what is possible for cancer patients. Our lead program, ONX-1006, is a novel nanoparticle reformulation of paclitaxel designed to enable sustained treatment with the potential for profound tumor reduction while minimizing treatment-related toxicity in pancreatic cancer. We exist to empower patients and their families to live fully, without cancer defining their days.
Onselex adheres to sound principles, acts with integrity, and never compromises its values.
Onselex pursues the highest standards with passion and dedication to improve patients’ lives and become a leading biopharmaceutical company.
Onselex respects individual differences and diversity, listens closely to patients’ needs, and strives to ease their suffering.
Onselex sets ambitious goals, embraces thoughtful risk-taking, and advances new possibilities through innovative ideas.